Cobenfy is the first schizophrenia drug in decades to treat the mental health condition in a new way, with potentially fewer ...

Methylene blue and red light therapy are showing promise for treating depression. Read on to learn how these therapeutics may ...

Recent research is painting a clearer picture of the link between the use of clozapine for schizophrenia and respiratory ...

Bristol-Myers Squibb Company (BMY) shares rose 1.6% after the FDA approved its new drug for schizophrenia. Shares of Cassava Sciences (SAVA) plunged 10.6% after the company reached a $40 million ...

The FDA approved a new drug for schizophrenia. Discrimination is stressing Chinese Americans and damaging their mental health.

Bristol Myers Squibb's drug, KarXT, improved symptoms of adults with schizophrenia and had fewer side effects than ...

ASX could hit record high despite mixed bag on Wall Street. US stocks expected to outperform bonds as Fed cuts rates.

Bristol Myers gains FDA approval for a new schizophrenia drug. HHS declares a health emergency in Georgia due to Hurricane ...

While momentous, the approval of Cobenfy could also draw attention to an age-old problem in American healthcare: Will insurance barriers keep patients from getting an effective medicine?

Experts expressed enthusiasm Friday after US health regulators approved the first new form of treatment for schizophrenia in ...

NEW YORK -- New York City Mayor Eric Adams pleaded innocent Friday to federal bribery charges, rejecting claims that he accepted overseas travel, campaign cash and other perks from foreign interests ...

Bristol-Myers Squibb's stock is set to rise with FDA approvals, acquisitions, and a strong oncology portfolio, despite ...